LRRK2, GBA and SMPD1 Founder Mutations and Parkinson's Disease in Ashkenazi Jews

Dementia and Geriatric Cognitive Disorders

Volumn 42, Issue 1-2, 2016, Pages 1-6

  Dagan, Efrat ^a   Schlesinger, Ilana ^b,c   Kurolap, Alina ^c,d   Ayoub, Mareemar ^d   Nassar, Maria ^c   Peretz Aharon, Judith ^b,c   Gershoni Baruch, Ruth ^b,d  

^a UNIVERSITY OF HAIFA   (Israel)

^b Rambam Health Care Campus   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d Institute of Human Genetics   (Israel)

Author keywords

Gaucher disease; GBA; LRRK2; Niemann Pick disease; Parkinson's disease; SMPD1

Indexed keywords

GLUCOSIDASE; GLUCOSIDASE BETA ACID; LEUCINE RICH REPEAT KINASE 2; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELIN PHOSPHODIESTERASE 1; UNCLASSIFIED DRUG; GLUCOSYLCERAMIDASE; LRRK2 PROTEIN, HUMAN; SPHINGOMYELIN PHOSPHODIESTERASE 1, HUMAN;

ADULT; AGED; ARTICLE; ASHKENAZI JEW; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCLE RIGIDITY; ONSET AGE; PARKINSON DISEASE; POST HOC ANALYSIS; PRIORITY JOURNAL; TREMOR; GENETIC PREDISPOSITION; GENETICS; ISRAEL; JEW; MUTATION; NEUROPSYCHOLOGICAL TEST; PROCEDURES; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; SYMPTOM ASSESSMENT; VERY ELDERLY;

AGE OF ONSET; AGED; AGED, 80 AND OVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUCOSYLCERAMIDASE; HUMANS; ISRAEL; JEWS; LEUCINE-RICH REPEAT SERINE-THREONINE PROTEIN KINASE-2; MALE; MUTATION; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; SPHINGOMYELIN PHOSPHODIESTERASE; SYMPTOM ASSESSMENT;

EID: 84980349922     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000447450     Document Type: Article

References (31)

1. Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33-39.
2. De Lau LM, Breteler MM: Epidemiology of Parkinson disease. Lancet Neurol 2006; 5: 525-535.
3. Lang AE, Lozano AM: Parkinson's disease. N Engl J Med 1998; 339: 1044-1053.
4. Crosiers D, Theuns J, Cras P, Van Broeckhoven C: Parkinson disease: insights in clinical, genetic and pathological features of monogenic disease subtypes. J Chem Neuroanat 2011; 42: 131-141.
5. Grunblatt E: Parkinson's disease: molecular risk factor. Parkinsonism Relat Disord 2012; 18(suppl 1):S45-S48.
6. Kurz MW, Schlitter AM, Larsen JP, Ballard C, Aarsland D: Familial occurrence of dementia and parkinsonism: a systematic review. Dement Geriatr Cogn Disord 2006; 22: 288-295.
7. Hernandez DG, Reed X, Singleton AB: Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. J Neurochem 2016, Epub ahead of print.
8. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt AL, Klein C, Henick B, Hailpern SM, Lipton RB, Soto-Valencia J, Risch N, Bressman SB: LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006; 354: 424-425.
9. Marras C, Schule B, Munhoz RP, Rogaeva E, Langston JW, Kasten M, Meaney C, Klein C, Wadia PM, Lim SY, Chuang RS, Zadikof C, Steeves T, Prakash KM, de Bie RM, Adeli G, Thomsen T, Johansen KK, Teive HA, Asante A, Reginold W, Lang AE: Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 2011; 77: 325-333.
10. Alcalay RN, Mejia-Santana H, Tang MX, Rosado L, Verbitsky M, Kisselev S, Ross BM, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Caccappolo E, Ottman R, Clark LN, Marder KS: Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. Arch Neurol 2009; 66: 1517-1522.
11. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R: Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004; 351: 1972-1977.
12. Gan-Or Z, Giladi N, Rozovski U, Shifrin C, Rosner S, Gurevich T, Bar-Shira A, Orr-Urtreger A: Genotypephenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 2008; 70: 2277-2283.
13. Sidransky E, Nalls MA, Aasly JO, et al: Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009; 361: 1651-1661.
14. Gan-Or Z, Ozelius LJ, Bar-Shira A Saunders-Pullman R, Mirelman A, Kornreich R, Gana-Weisz M, Raymond D, Rozenkrantz L, Deik A, Gurevich T, Gross SJ, Schreiber-Agus N, Giladi N, Bressman SB, Orr-Urtreger A: The p. L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. Neurology 2013; 80: 1606-1610.
15. Dagan E, Schlesinger I, Ayoub M, Mory A, Nassar M, Kurolap A, Peretz-Aharon J, Gershoni-Baruch R: The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews. Parkinsonism Relat Disord 2015; 21: 1067-1071.
16. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW; International LRRK2 Consortium: Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7: 583-590.
17. Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, Gurevich T, Yagev-More H, Bar-Shira A, Giladi N: The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect Neurology 2007; 69: 1595-1602.
18. Horowitz M, Pasmanik-Chor M, Borochowitz Z, Falik-Zaccai T, Heldmann K, Carmi R, Parvari R, Beit-Or H, Goldman B, Peleg L, Levy-Lahad E, Renbaum P, Legum S, Shomrat R, Yeger H, Benbenisti D, Navon R, Dror V, Shohat M, Magal N, Navot N, Eyal N: Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population. Hum Mutat 1998; 12 240-244.
19. Aharon-Peretz J, Badarny S, Rosenbaum H, Gershoni-Baruch R: Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype-genotype correlation. Neurology 2005; 65: 1460-1461.
20. Neudorfer O, Giladi N, Elstein D, Abrahamov A, Turezkite T, Aghai E, Reches A, Bembi B, Zimran A: Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 1996; 89: 691-694.
21. Tayebi N, Callahan M, Madike V, Stubblefield BK, Orvisky E, Krasnewich D, Fillano JJ, Sidransky E: Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 2001; 73: 313-321.
22. Beavan M, McNeill A, Proukakis C, Hughes DA, Mehta A, Schapira AH: Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. JAMA Neurol 2015; 72: 201-208.
23. Gan-Or Z, Amshalom I, Kilarski LL, Bar-Shira A, Gana-Weisz M, Mirelman A, Marder K, Bressman S, Giladi N, Orr-Urtreger A: Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology 2015; 84: 880-887.
24. Gan-Or Z, Orr-Urtreger A, Alcalay RN, Bressman S, Giladi N, Rouleau GA: The emerging role of SMPD1 mutations in Parkinson's disease: implications for future studies. Parkinsonism Relat Disord 2015; 21: 1294-1295.
25. Platt FM: Sphingolipid lysosomal storage disorders. Nature 2014; 510: 68-75.
26. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
27. Fahn S, Elton RL: Members of the Unified Parkinson's Disease Rating Scale Development Committee. Unified Parkinson's Disease Rating Scale; in Fahn S, Marsden CD, Goldstein M, Calne DB (eds): Recent Developments in Parkinson's Disease. New York, Macmillan, 1987, pp 153-163.
28. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
29. Dehay B, Martinez-Vicente M, Caldwell GA, Caldwell KA, Yue Z, Cookson MR, Klein C, Vila M, Bezard E: Lysosomal impairment in Parkinson's disease. Mov Disord 2013; 28: 725-732.
30. Deng H, Xiu X, Jankovic J: Genetic convergence of Parkinson's disease and lysosomal storage disorders. Mol Neurobiol 2015; 51: 1554-1568.
31. Coutinho MF, Matos L, Alves S: From bedside to cell biology: a century of history on lysosomal dysfunction. Gene 2015; 555: 50-58.